- Home
- RDWR vs STOK Comparison
RDWR vs STOK Comparison
Compare RDWR & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- STOK
- Stock Information
- Founded
- RDWR 1996
- STOK 2014
- Country
- RDWR Israel
- STOK United States
- Employees
- RDWR N/A
- STOK N/A
- Industry
- RDWR EDP Services
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- STOK Health Care
- Exchange
- RDWR Nasdaq
- STOK Nasdaq
- Market Cap
- RDWR 849.8M
- STOK 838.2M
- IPO Year
- RDWR 1999
- STOK 2019
- Fundamental
- Price
- RDWR $21.04
- STOK $14.53
- Analyst Decision
- RDWR Buy
- STOK Strong Buy
- Analyst Count
- RDWR 2
- STOK 7
- Target Price
- RDWR $23.00
- STOK $21.40
- AVG Volume (30 Days)
- RDWR 128.3K
- STOK 406.3K
- Earning Date
- RDWR 10-30-2024
- STOK 11-05-2024
- Dividend Yield
- RDWR N/A
- STOK N/A
- EPS Growth
- RDWR N/A
- STOK N/A
- EPS
- RDWR N/A
- STOK N/A
- Revenue
- RDWR $259,005,000.00
- STOK $15,157,000.00
- Revenue This Year
- RDWR $5.93
- STOK $78.03
- Revenue Next Year
- RDWR $6.81
- STOK $12.23
- P/E Ratio
- RDWR N/A
- STOK N/A
- Revenue Growth
- RDWR N/A
- STOK 71.38
- 52 Week Low
- RDWR $13.53
- STOK $3.35
- 52 Week High
- RDWR $23.05
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- RDWR 49.11
- STOK 49.87
- Support Level
- RDWR $19.72
- STOK $13.62
- Resistance Level
- RDWR $22.87
- STOK $15.92
- Average True Range (ATR)
- RDWR 0.52
- STOK 0.91
- MACD
- RDWR -0.16
- STOK -0.04
- Stochastic Oscillator
- RDWR 48.37
- STOK 42.29
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. The company generates maximum revenue from the United States.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.